MAPT and Alzheimer disease: Although we did not see a group-wise difference between control and AD patients, which is in line with earlier studies from other labs [18,19,34], we found clear correlations with tau measures, NF-L, and the Aβ ratio, and—at least for brevican—also with the MMSE score.